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ABSTRACT
U1 Adaptors are a recently reported novel approach
for targeted reduction of mRNA transcripts. A U1
adaptor oligonucleotide comprising of a target-
complimentary hybridization domain and a U1 recruit-
ment domain, directs the U1 snRNP complex to the
terminal exon of a targeted gene, subsequently
inhibiting poly(A) tail addition and leading to degrad-
ation of that RNA species within the nucleus.
Here, we present data demonstrating U1 adapter-
mediated gene silencing can result in significant
‘off-target’ silencing effects as demonstrated by
the reduction of multiple mRNA species that were
not intended to be targeted. Our data suggest that a
substantial portion of this U1 adaptor-mediated off-
target mRNA reduction is the result of sequestration
U1 snRNP at levels sufficient to affect splicing and
processing of non-target transcripts.
INTRODUCTION
Recently, an approach for reducing gene expression based
on  25-nt sequences called U1 adaptors was reported (1).
U1 adaptors are comprised of a 50 sequence or ‘target do-
main’, which hybridizes to the ﬁnal exon of an mRNA
target and a 30 sequence or ‘U1 domain’ that binds to
the U1 small nuclear RNA component of the U1 small
nuclear ribonucleoprotein (U1 snRNP). Reportedly,
tethering U1 snRNP to the target pre-mRNA inhibits
poly(A)-tail addition, causing degradation of that RNA
in the nucleus. U1 adaptors were reported to inhibit
both endogenous and reporter genes in a sequence-speciﬁc
manner and it was determined that the reductions in target
RNAs were quite selective.
The U1snRNP is comprised of the 164nt U1 small
nuclear RNA (snRNA) and 10 associated polypeptides.
A component of the cellular splicing apparatus, it is
best-known for its role in recognizing the 50-splice sites
of introns through hybridization between these sequences
and the 50-end of U1 snRNA (2). Together with SF2/ASF
and hnRNP A1, the U1 snRNP modulates alternative
50-splice site selection (3,4). In addition, the U1 snRNP
also inhibits polyadenylation of some pre-mRNAs by
binding to a 50-splice-site-like sequence in the 30-untrans-
lated region (30-UTR), leading to degradation of the
pre-mRNA (5,6).
It has been reported that sequestration of U1 snRNP by
speciﬁc, transiently expressed RNA decoys, changes the
splicing of reporter pre-mRNAs (7). Since U1 adaptors
rely on the binding of endogenous U1 snRNP to the
target RNA, sequestration of U1 snRNPs by a U1
adaptor might be expected to affect the splicing of multiple
transcripts in the cell. In addition to inhibiting splicing,
U1 snRNP knockdown has also recently been demon-
strated to cause premature cleavage and polyadenylation
in numerous pre-mRNAs at cryptic polyadenylation
signals (8). U1 adaptors may, therefore, have unintended
effects on splicing and polyadenylation, potentially
limiting the utility of the approach.
In this article, we show that U1adaptors non-speciﬁcally
and signiﬁcantly reduce expression of non-targeted genes.
Our data suggest that a signiﬁcant proportion of the non-
speciﬁc activity is the result of the sequestering of U1
snRNP by U1 adaptors. Using a minigene splicing
system, we demonstrate signiﬁcant effects of U1 adaptor
treatment on splicing that are similar to those observed
when U1 snRNA is intentionally reduced. We also dem-
onstrate transcriptome-wide effects on gene expression
and splicing, not related to speciﬁc reduction of the
intended U1 adaptor target, but resulting instead from
errors in processing of pre-mRNA. The magnitude of
this activity appears to be a function of the sequence of
the U1 adaptor and the mRNA targeted.
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Preparation of U1 adaptors and antisense oligonucleotides
The U1 adaptors targeting RAF1, PCSK9 and SMN2
were manufactured by Integrated DNA Technologies
(IDT). The sequences of the RAF1 (UA25) and PCSK9
(UA31e) U1 adaptors have been previously described (1).
Synthesis and puriﬁcation of phosphorothioate/20-MOE
oligonucleotides was performed using an Applied
Biosystems 380B automated DNA synthesizer as desc-
ribed previously (9). RNAse H-dependent antisense oligo-
nucleotide (ASOs) used for target mRNA reduction
were 18–20 bases in length, full phosphorothioate with
20-O-methoxyethyl substitutions at the positions indicated
by bold type. The sequences and chemistry of the U1
adaptors and ASOs used in the study are depicted in
Table 1.
qRT/PCR primer/probes
The sequence for the RAF1 primer/probe set used in qRT/
PCR reactions is AGCTTGGAAGACGATCAGCAA for
the forward primer, AAACTGCTGAACTATTGTAGG
AGAGATG for the reverse primer and AGATGCCGTG
TTTGATGGCTCCAGC for the probe. The sequence for
the SMN2 primer/probe set is CAGGAGGATTCCGTG
CTGTT for the forward primer, TCAGTGCTGTATCAT
CCCAAATG for the reverse primer and CGGCACAGG
CCAGAGCGATG for the probe. The sequence for the
PTEN primer/probe set is AATGGCTAAGTGAAGAT
GACAATCAT for the forward primer, TGCACATATC
ATTACACCAGTTCGT for the reverse primer and TTG
CAGCAATTCACTGTAAAGCTGGAAAGG for the
probe. The sequence for the PCSK9 primer/probe set is
CCTGCGCGTGCTCAACT for the forward primer, GC
TGGCTTTTCCGAATAAACTC for the reverse primer
and CCAAGGGAAGGGCACGGTTAGCG for the
probe. The sequence for the YY1 primer/probe set GCG
AATCCATACCGGAGACA for the forward primer, AG
GTTAGTTGACTGAGCAAACTTCTTATT for the
reverse primer and CCCTATGTGTGCCCCTTCGATG
GTT for the probe. The sequence for the IL4R primer/
probe set is AGACCCCCAAAATCGTGAACT for the
forward primer, TGGATAAGCCCTAGTCCTCATCT
G for the reverse primer and CATACATGAGGGTCTC
TTAGGTGCAT for the probe. Probe Chemistry: 50FAM,
30TAMRA.
U1 adaptor/ASO treatment
Tissue culture medium, trypsin and lipofectamine 2000
and T-REX-293 cells were purchased from Invitrogen
(Carlsbad, CA, USA). HeLa cells were obtained from
the American Type Tissue Collection (Manassas, VA,
USA). HeLa cells were cultured in DMEM supplemented
with 10% fetal calf serum, streptomycin (0.1mg/ml) and
penicillin (100U/ml). The same media was used for
T-REX-293 cells with the addition of 5mg/ml blasticidin.
Cells were seeded in 96-well plates at  50% conﬂuency
then treated the following day with the indicated concen-
trations of ASO/U1 adaptor in Opti-MEM media
(Invitrogen) containing 4–5mg/ml lipofectamine 2000 for
4–5h, as described previously (10). Following, transfec-
tion cells were washed 1  with PBS, then fed with fresh
growth media. The next day, total RNA was puriﬁed
using an RNeasy 3000 BioRobot (Qiagen, Valencia, CA,
USA) and mRNA levels assessed by qRT/PCR performed
essentially as described elsewhere (11). Brieﬂy, 10mlo f
total RNA was analyzed in a ﬁnal volume of 50ml con-
taining 200nM gene-speciﬁc PCR primers, 0.2mM of
each dNTP, 75nM ﬂuorescently labeled oligonucleotide
probe, 5ml RT–PCR buffer, 5mM MgCl2,2 Uo f
Platinum Taq DNA Polymerase (Invitrogen) and 8U of
RNAse inhibitor. Reverse transcription was performed
for 30min at 48 C followed by PCR: 40 thermal cycles
of 30s at 94 C and 1min at 60 C using an ABI Prism 7700
Sequence Detector (Applied Biosystems). To avoid arti-
facts based upon well to well variation in cell number,
mRNA levels were normalized to the total amount of
RNA present in each reaction as determined by
Ribogreen assay (12) (Invitrogen). The sequences of the
primer/probe sets are listed in Supplementary Materials.
Northern analysis of U1 snRNA was carried out as
follows. Cells plated in 10cm dishes were treated with
U1 snRNA directed ASOs at 50–100nM using
lipofectamine 2000 as described above. Total RNA was
Table 1. Oligonucleotides used in study
Name/number Chemistry Target Sequence (50–30)
U1A-RAF1 U1 Adaptor RAF1 CCGCCTGTGACATGCATTcagguaaguau
U1A-SMN2 U1 Adaptor SMN2 CGCTTCACATTCCAGATCTGcagguaaguau
U1A-PCSK9 U1 Adaptor PCSK9 CTCGCAGGCCACGGTCACgccagguaaguau
194166 RNaseH ASO RAF1 TCCCGCCTGTGACATGCATT
13649 Full MOE ASO RAF1 TCCCGCCTGTGACATGCATT
450880 RNaseH ASO SMN2 CGCTTCACATTCCAGATCTG
469892 RNaseH ASO PCSK9 CTCGCAGGCCACGGTCAC
469508 RNaseH ASO RNU1 CTCCCCTGCCAGGTAAGTAT
469509 RNaseH ASO RNU1 ATCCGGAGTGCAATGGATAA
469511 RNaseH ASO RNU1 CTACCACAAATTATGCAGTC
479333 RNaseH ASO RNU4 GGTATTGGGAAAAGTTTTCA
479338 RNaseH ASO RNU6 CCATGCTAATCTTCTCTGTA
For U1 adaptors upper case=DNA, bold=LNA, lower case=20OMe. For ASOs upper case=P=S DNA bold= 20-O-
methoxyethyl.
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according to the manufacturer’s protocol. Total of 5mg
RNA was separated in 8% ployacrylamide–7M urea
gels, then transferred to GeneScreen Plus Hybridization
Transfer Membranes (PerkinElmer) using a semi-dry
transfer apparatus. Northern hybridization was per-
formed using
32P5 0-end labeled oligonucleotide probes
as described previously (13). U1-1: agtcgagtttcccacatttg;
U1-2: CTCCCCTGCCAGGTAAGTAT; U6: tggaacgctt-
cacgaatttgcg; U3: accactcagaccgcgttctctcc.
RNAse H protection assays
RNAse H protection assays were performed using a modi-
ﬁcation of a protocol described by Kaida et al. (8). Brieﬂy,
250000 cells were transfected with U1 adaptor or ASO for
6h as detailed above. Cells were washed with PBS and
harvested following trypsinzation. The cell pellet was re-
suspended in 50ml of RSB-100 buffer (10nM Tris–HCl,
pH 7.4, 100mM NaCl, 2.5mM MgCl, 0.1% NP-40 and
1mM DTT). Cells were rotated at 4 C for 20min, then
centrifuged at 10000rpm for 5min. A 40ml of cleared cell
extract was incubated with 2mM DNA ASO complimen-
tary to the U1 snRNA 50-end (50-CAGGTAAGTAT-30),
2U Escherichia coli RNAse H (New England Biolabs) for
30min at 30 C. Total RNA was then puriﬁed using an
RNeasy Mini Kit (Qiagen). U1 snRNA was analyzed by
northern blot as described above.
For cellular protection assays, 293 cells were transfected
with U1 adaptor or ASO for 3h. Following a 1h recovery,
cells were transfected with ASO 469508 at 50nM for 4h.
Isolation of total RNA and northern hybridization were
then carried out as described above.
TET-inducible minigene system
An SMN2 mini gene, comprising the 111-nt long exon 6, a
200-nt shortened intron 6, the 54-nt exon 7, the 444-nt
intron 7, the ﬁrst 75nt of exon 8, under the control of
the CMV and T7 RNA polymerase promoter has been
previously described (14). We ampliﬁed the minigene
with primer set SMN2–Hind3F (AAG CTT aag gct aga
gta ctt aat acg act cac) and SMN2–Xba1R (TCT AGA
TAA CGC TTC ACA TTC CAG ATC TG), and inserted
them into vector into the vector pcDNA 4/TO using
HindIII and XbaI restriction sites. The forward primer
is complementary to the T7 promoter from pCI-SMN2
and incorporates a HindIII site, while the reverse primer
was complementary to the 30-end of the truncated exon 8
and included a XbaI site. The resultant plasmid, pcSMN2/
TO, was transfected into T-REx-293 cells (Invitrogen,
Carlsbad, CA, USA), using Effectene transfection reagent
according to the manufacturer’s protocol (Qiagen,
Valencia CA, USA). Cell lines stably integrating the
mini gene were selected in DMEM media containing
250ug/ml Zeocin. Zeocin-resistant colonies were expanded
then tested for tetracycline-inducible expression.
Following TET induction, total RNA was puriﬁed
using RNeasy mini columns according to the manufactur-
er’s protocol (Qiagen). Expression of pcSMN2/TO
full-length, skipped and pre-mRNA was determined by
qRT/PCR as detailed above. To avoid ampliﬁcation of
endogenous SMN1/2, all mRNA isoforms shared the
same forward primer, T7F2 (TAC TTA ATA CGA
CTC ACT ATA GGC TAG CCT CG) which is compli-
mentary to the T7 promoter region (lower case) on
pcSMN2/TO. To speciﬁcally amplify full-length message
a reverse primer bridging the exon 6/7 junction, SMN-E6/
7R, was employed (TTT TGT CTA AAA CCC ATA
TAA TAG CC). Exon 7 skipped mRNA was ampliﬁed
with a reverse primer bridging the exon 6/8 junction,
SMN-E6/8R (ATG CCA GCA TTT CCA TAT AAT
AGC). For pre-mRNA ampliﬁcation the reverse primer,
SMN-I6R, was designed with complementarity to intron 6
(TGT CAG GAA AAG ATG CTG AGT G). A common
probe, SMN-E6P, complementary to sequence in exon 6
was used in all reactions (6FAM-CAG ATT CTC TTG
ATG ATG CTG ATG CTT TGG- IABkFQ).
Affymetrix exon arrays
The Affymetrix GeneChip Human Exon 1.0 ST Array
platform was used for the microarray analysis. The deter-
mination of signiﬁcant differential expression was per-
formed using functions from the ‘Bioconductor’ (15)
suite of packages including ‘exonmap’ (16,17) and
‘limma’ (18). The detection of probes showing differential
expression was determined by ANOVA using the limma
package. P-values were adjusted for multiple testing using
the method of Benjamini and Hochberg (19). Probes with
adjusted P<0.01 were called differentially expressed.
Differentially expressed probes were divided into exonic
or intronic probes via exonmap.
RESULTS
Evaluation of U1 adaptor speciﬁcity
To discriminate potential off-target effects due to seques-
tration of U1 snRNP by U1 adaptors from those resulting
from binding to the mRNA target alone, we evaluated the
activity of several U1 adaptors along with ASOs targeted
to the same site on the mRNA. An ASO would be
expected to bind the targeted mRNA transcript with an
afﬁnity similar to that of the U1 adaptor target domain
without recruitment of the U1 snRNP, allowing a direct
comparison with the alternate degradation mechanism
proposed for U1 adaptors. HeLa cells were transfected
at 100nM with a U1 adaptor, a fully 20-O-methoxyethyl
ribose (20MOE) ASO, or a chimeric 20MOE/DNA ASO
targeted to the same site on RAF1 mRNA. Target mRNA
reduction was evaluated by qRT/PCR the following day
(Figure 1). The RNAse H-dependent ASO (194166)
reduced RAF1 mRNA (solid bars) by >85%, with little
reduction of levels of SMN2 (striped bars) or PTEN
(hatched bars) non-target messages observed. Treatment
with the RAF1 U1 adaptor (U1A-RAF1) at the same
concentration resulted in a  90% reduction in RAF1
mRNA. In addition, the level of PTEN mRNA was
reduced by approximately the same amount, while
SMN2 mRNA was reduced by  75%. Treatment with
ASO 13496, which does not support cleavage by
RNAse H (20), resulted in no signiﬁcant reduction of
either RAF1 or non-target mRNAs. The lack of activity
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cannot be responsible for speciﬁc or non-speciﬁc mRNA
reduction resulting from treatment with the U1 adaptor or
RNase H-dependent ASO.
Since it has been reported that IC50’s of <5nM can
be achieved with U1 adaptors (1), we wanted to deter-
mine if a window of speciﬁc target reduction could be
observed at lower treatment concentrations. HeLa cells
were transfected with U1A-RAF1, a second U1 adaptor
targeted to SMN2 (U1A-SMN2) or the corresponding
RNAse H-dependent ASOs at multiple concentrations.
Expression of RAF1 mRNA was reduced by U1A-
RAF1 with an IC50 of  20nM (Figure 2a). U1A-
SMN2 also effectively reduced RAF1 mRNA with
approximately the same IC50. Reduction of SMN2
mRNA was also evaluated (Figure 2b). While U1A-
SMN2 reduced expression of the targeted RNA with an
IC50 of  3nM, off-target reduction of SMN2 by U1A-
RAF1 was less robust with an IC50 of  75nM. Both U1
adaptors also effectively reduced expression of PTEN, an
unrelated, non-target mRNA, with an IC50 of  25nM for
U1A-RAF1 and  10nM for U1A-SMN (Figure 2c). ASO
194166 (RAF1) was  7-fold more potent than the corres-
ponding U1 adaptor, while ASO 450880 (SMN2) and the
corresponding U1 adaptor were equipotent. No signiﬁcant
reduction in non-targeted messages was observed for
either ASO. Similar levels of reduction in non-targeted
transcripts were observed in primary human umbilical
vein endothelial cells (HUVEC) and in 293T cells treated
with U1 adaptors (Supplementary Figure S1). Together,
these data suggest that transcripts may be differentially
sensitive to U1 adaptor-mediated off-target activity and
that off-target activity can vary by site and target.
ASO-mediated knockdown of U1 snRNP
To directly evaluate and compare the contribution of U1
snRNP reduction with U1 adaptor off-target activity, we
sought to decrease the amount of functional U1 snRNP
Figure 2. Potency and speciﬁcity of U1 adaptors and RNAse H ASOs.
A second U1 adaptor was designed to target SMN2 (U1A-SMN2).
HeLa cells were treated at concentrations of 3nM, 10nM, 30nM, or
100nM with U1A-SMN2, U1A-RAF1, ASO 194166 (RAF1) or ASO
450880 (SMN2). After 24h, cells were harvested and RNA puriﬁed.
Messenger RNA reduction was analyzed by qRT/PCR. The percent
mean mock-treated control (UTC) for three to four replicates and
the standard error is shown for each concentration. (a) Percent
control RAF1 mRNA expression. (b) Percent control SMN2 mRNA
expression. (c) Percent control PTEN mRNA expression.
Figure 1. U1 adaptor downregulates multiple mRNAs. A U1 adaptor
targeted to RAF1 (U1A-RAF1) was administered to Hela cells at a
single-dose of 100nM. A fully modiﬁed 20MOE ASO (13649) and a
chimeric 20MOE/DNA RNAse H-dependent ASO (194166)
complementary to the same target sequence were also administered at
the same concentration. After 24h, cells were harvested, RNA was
puriﬁed and mRNA reduction assayed by qRT/PCR using primers
speciﬁc for 3 mRNAs; RAF1, PTEN and SMN2. The bars represent
per cent mean untreated control for three replicates and the standard
errors. UTC=mock-treated control.
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tarity to U1 snRNA (Figure 3a). HeLa cells were trans-
fected with the ASOs at concentrations ranging from
50nM to 200nM. The following day, total RNA was
puriﬁed and U1snRNA reduction analyzed by northern
blot. Blots hybridized with the internal U1 northern
probe (U1-1) showed a signiﬁcant shift in the migration
of U1snRNA following treatment with 469508 consistent
with cleavage of the 50 U1 snRNA binding sequence, even
at the lowest concentration evaluated (Figure 3a and b,
upper panel). However, the lack of reduction in signal
intensity suggests that there is little degradation of the
U1 snRNA following RNaseH cleavage, likely due to
the highly structured nature of the RNA target. To
conﬁrm this, the same blot was hybridized with a second
Northern probe, U1-2, complimentary to the cleaved U1
snRNA 50-end (Figure 3b, lower panel). As observed with
probe U1-1, treatment with ASO 469508 resulted in a shift
in mobility consistent with the expected U1 snRNA
cleavage product. In addition, a clear reduction in U1
snRNA was observed using probe U1-2, with >75% re-
duction of U1 snRNA at 50nM and >90% reduction at
200nM (normalized to the U6 snRNA loading control).
Together, these data conﬁrm that treatment with 469508
efﬁciently directs RNAse H cleavage of the U1 leader
sequence previously shown to be required for U1
splicing activity (8). The other ASOs evaluated, 469509
and 469511, each produced cleavage fragments consistent
with their localization on the target, however, the potency
of these ASOs was much less than that of 469508.
We next evaluated the effects of U1 snRNA inactiva-
tion with ASO 469508 as compared to U1 adaptor treat-
ment. HeLa cells seeded in 96-well plates were treated in
triplicate with anti-U1 ASO 469508 or with U1A-RAF1,
U1A-SMN2 or U1A-PCSK9 at concentrations ranging
from 6nM to 200nM. After 16h, levels of targeted and
non-targeted mRNA were evaluated by qRT/PCR. U1A-
PCSK9 and U1A-SMN2 both effectively reduced target
mRNAs with IC50’s <10nM (Figure 3c). U1A-PCSK9
and U1A-SMN2 also reduced non-target messages with
IC50’s between 10nM and 25nM. U1A-RAF1 was
 5-fold less potent, with an IC50 of  50nM for both
target and non-target mRNAs. Levels of each mRNA
were also decreased as a result of U1 snRNA reduction
with ASO 469508. PCSK9, RAF1 and PTEN mRNA
were all reduced to levels comparable to the U1 adaptor
off-target reduction for each of these messages with IC50’s
of 20–50nM. SMN2 RNA was also reduced following
treatment with ASO 469508; however, the IC50 of
 100nM was signiﬁcantly greater than that observed for
the speciﬁc or non-target U1 adaptors.
To further evaluate off-target effects, HeLa cells were
treated with U1A-SMN2, ASO 450880 and ASO 469508
at concentrations from 12.5 to 100nM. The following day,
expression of a panel of mRNAs was evaluated by qRT/
PCR. Treatment with U1A-SMN2 resulted in an IC50 for
SMN2 mRNA expression of  10nM (Figure 4a).
Non-target mRNAs were also effectively reduced by treat-
ment with U1A-SMN2 with IC50’s between 20 and
100nM, and even at the lowest concentration, signiﬁcant
reduction was observed for several of the non-target
transcripts. Treatment with anti-U1 snRNA ASO
469508 also resulted in reduction of the same set of tran-
scripts with similar IC50’s (Figure 4b). Note that, as in
Figure 3c, SMN2 was the target least affected by disabling
of U1 snRNA, suggesting that for this mRNA, a signiﬁ-
cant proportion of the observed activity for the U1
adaptor is speciﬁc and mediated by the proposed mechan-
ism. For other targets, such as PCSK9 (Figure 3c) and
PIK3CB (compare Figure 4a and b), the similarity of
the potency of mRNA reduction between the U1
adaptor and U1 snRNA reduction suggests that the
activity is more related to the effects U1snRNP sequestra-
tion by the U1 adaptor rather than the proposed speciﬁc
deadenylation/degradation of the message mediated by
the U1 adaptor. SMN2 ASO 450880 had approxi-
mately the same IC50 as the corresponding U1 adaptor,
but with no signiﬁcant activity observed at 10nM for
the other mRNA targets and only slight reduction
observed for some transcripts at the highest concentration
(Figure 4c), again indicating that the observed off-target
activity is speciﬁc to treatment with U1 adaptors. These
results were conﬁrmed and expanded, as an even larger
number of overlapping transcripts were identiﬁed by
PCR array as being reduced by treatment with U1A-
RAF1 and the anti-U1 ASO 469508, but not by the cor-
responding RNAse H-dependent ASO (Supplementary
Figure S2).
U1 adaptors sequester U1 snRNP
To verify that U1 adaptors sequester U1 snRNP, we per-
formed RNAse H protection assays (Figure 5a). Extracts
from cells transfected with U1A-RAF1 and U1A-SMN2
or with the corresponding RNAse H ASOs were incubated
with E. coli RNAse H and a DNA ASO probe compli-
mentary to the U1 snRNA 50 leader sequence. In extracts
prepared from untreated cells or cells treated with ASOs, a
fragment corresponding to the size expected for RNAse H
cleavage was observed. However, in extracts from cells
treated with either U1 adaptor, no cleavage product was
observed, indicating that the U1 adaptor prevented
binding of the DNA ASO probe and subsequent RNAse
H digestion.
Cellular RNAse H protection assays were also per-
formed. 293T cells were treated with U1A-SMN2 at con-
centrations ranging from 10 to 200nM or with the
corresponding target ASOs at 200nM. Cells were then
transfected with anti-U1 RNAse H ASO 469508 and U1
snRNA cleavage assessed by northern blot. In the absence
of 469508 no cleavage of U1 snRNA was observed (Figure
5b, Lane 1). Approximately 50% cleavage was observed in
the absence of the U1 adaptor (Lane 2); however, cleavage
was reduced in the presence of U1A-SMN2 with nearly
complete blocking of RNAse H cleavage by 469508 at
100nM and an IC50 of  35nM. Treatment with The
RNAse H ASO 450880 or with the target portion of the
U1 adaptor only (SMN2-T) had no effect on RNAse H
cleavage of U1 snRNA. U1A-RAF1 and U1A-PCSK9
were also evaluated in this assay and found to block
RNAse H cleavage of U1 snRNA with IC50’s of 50 and
20nM, respectively (data not shown). These data strongly
PAGE 5 OF 12 Nucleic Acids Research,2011, Vol.39, No. 10 e71Figure 3. Reduction of U1 snRNA with RNAse H ASOs. (a) Chimeric 20MOE/DNA RNAse H-dependent ASOs were designed to target
U1snRNA. The location of 3 RNAse H ASOs is underlined on the U1 snRNA sequence. 469508 (1–20), 469509 (59–78), 469511 (117–138).
Northern probe location is highlighted on the U1 snRNA structure. (b) HeLa cells were treated with ASOs at the indicated concentrations (nM).
The following day total RNA was puriﬁed and U1snRNA reduction analyzed by northern blot with the internal U1 probe (U1-1, upper panel), or
with a second probe, U1-2, targeted to the U1 50-end and the non-target control and U6 snRNA probe (lower panel). Band intensity was quantitated
with a Storm 850 Phosphor-Imager and U1 snRNA normalized to U6 snRNA signal for each lane. (c) Effect of U1 adaptor treatment and U1
snRNA reduction on mRNA expression. HeLa cells seeded in 96-well plates were treated with U1A-RAF1, U1A-SMN2, U1A-PCSK9 or anti-U1
ASO 469508, in triplicate at concentrations ranging from 6 to 200nM. The following day total RNA was puriﬁed and mRNA levels of each targeted
gene assessed by qRT/PCR. Results are normalized to the total amount of RNA present in each reaction as determined by Ribogreen assay and
plotted as percent control compared to mock-treated cells for three to four replicates with the standard error.
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to sequestration of the U1 snRNP.
U1 adaptors alter splicing of pre-mRNA
Since reduction of U1 snRNP has been demonstrated to
result in alteration of splicing (7), we utilized an SMN2
minigene system to compare the effects of U1 adaptor
treatment and U1 snRNP reduction on alternative
splicing. The skipping of exon 7 of the SMN2 gene has
been well characterized (14). We subcloned the previously
reported SMN2 mini gene (21) into the tetracycline indu-
cible expression plasmid pcDNA 4/TO for stable integra-
tion into 293 cells (Figure 6a). SMN2/TO-293 cells were
induced with tetracycline at 0.25 ug/ml for 30min to 6h.
Expression of SMN/TO mRNA assessed using the
splice-form speciﬁc qRT/PCR primer/probe sets shown
in Figure 6b, demonstrated tightly regulated TET induc-
tion of the spliced full-length and exon 7 skipped mini
gene mRNA (Figure 6c). Reduction of U1 snRNA by
ASO 469508, as well as reduction of U4 and U6
snRNAs, was found to result in an increase in SMN2/
TO pre-mRNA levels (Supplementary Figure S3A). In
addition, reduction of U1, but not U4 or U6 snRNA
resulted in an increase in the ratio of skipped relative to
full-length spliced mRNA (Supplementary Figure S3B).
The effects of U1 adaptors on splicing in the SMN
minigene system were next evaluated. SMN/TO 293 cells
were treated with U1A-RAF, U1A-PCSK9, ASO 469508
(U1 snRNA) or ASO 479333 (U4 snRNA) at 50nM. The
following day SMN/TO expression was induced for 4h,
then expression of SMN/TO and target mRNA assessed.
Again, reduction of either U1 or U4 snRNA resulted in
an increase in the amount of SMN/TO pre-mRNA
(Figure 6d, solid bars). U4 snRNA reduction also led to
Figure 4. U1 adaptors and anti-U1 snRNA ASOs promote reduction
of multiple non-targeted mRNAs. HeLa cells were treated with
U1A-SMN2, SMN2 ASO 450880, or U1 ASO 469508 at concentrations
from 12.5 to 100nM. The following day cells were harvested and RNA
puriﬁed. Messenger RNA reduction was analyzed by qRT/PCR.
Percent mock-treated control expression is shown for the six transcripts
identiﬁed by Entrez Gene symbol at the bottom of the ﬁgure. (a) Cells
treated with U1A-SMN2. (b) Cells treated with anti-U1 RNAse H ASO
469508. (c) Cells treated with SMN2 RNAse H ASO 450880.
Figure 5. U1 adaptors bind the 50 sequence of U1 snRNA and inhibit
antisense hybridization. (a) 293-T cells were transfected with 100nM
U1 adaptor/ASO for 6h. RNAse H protection assays were performed
with whole-cell extracts±2U E. coli RNAse H and 2mM DNA oligo-
nucleotide antisense to the 50 sequence of U1. Cleavage of U1 snRNA
was detected by northern blot using internal U1 probe (U1-1), and
normalized using a U3 probe (U3). (b) Cellular RNAse protection
assay. Cells were treated with U1A_SMN2 or ASO at concentrations
ranging from 10 to 200nM as shown. Cells were then transfected with
anti U1 RNAse H ASO 469508 at 50nM and U1 snRNA cleavage
assessed by northern blot using internal U1 probe (U1-1). Band inten-
sity was quantitated with a Storm 850 Phosphor-Imager and U1
snRNA signal normalized to U3 for each lane.
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TO and of the PCSK9 and RAF1 mRNAs. As previously
observed, U1 snRNA reduction resulted in a change in the
ratio SMN/TO spliced mRNA, causing an increase in the
skipped (hatched bars) relative to the full-length (striped
bars) form, although overall expression of spliced SMN/
TO message was reduced relative to the untreated control.
Both U1 adaptors behaved similarly, with increases in
Figure 6. U1 adaptors and anti-U1 snRNA ASOs alter mini gene splicing and expression. (a) A tetracycline inducible SMN2 mini gene, comprised
of the 11-nt long exon 6, a 200-nt shortened intron 6, the 54-nt exon 7, the 444-nt intron 7, the ﬁrst 75nt of exon 8, from pCI-SMN2 was subcloned
into the vector pcDNA 4/TO using PCR generated HindIII and XbaI sites as detailed in the ‘Materials and Methods’ section. Stable TREX 293 cell
transformants from transfected cells were obtained by zeocin selection. (b) Location of qRT/PCR primers and probe used to amplify SMN/TO
full-length, exon 7 skipped, and pre-mRNA. (c) Kinetics of SMN/TO tetracycline induction. SMN2/TO-293 cells were treated with TET at 0.25 ug/
ml for 30min to 6h. Expression of SMN/TO mRNA assessed using the splice-form speciﬁc qRT/PCR primer/probe sets shown in Figure 5B and as
detailed in ‘Materials and Methods’ section. (d) SMN/TO 293 cells were treated with U1A-RAF, U1A-PCSK9, anti-U1 ASO 469508, or anti-U4
ASO 479333 at 50nM. The following day SMN/TO expression was induced for 4h, then expression of SMN/TO and target mRNA assessed. Results
are presented as percent mock-treated control (UTC) for each mRNA assayed. Pre-mRNA, ﬁlled bars; full-length SMN/TO mRNA, striped bars;
exon 7-skipped SMN/TO mRNA, hatched bars; RAF1 mRNA, gray bars; PCSK9 mRNA, open bars.
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to the full-length spliced message. Note that treatment
with U1A-RAF1 or U1A-PCSK9, as well as ASO
469508 or ASO 479333, reduced RAF1 to similar levels
as compared to control cells (gray bars), again
demonstrating virtually no selectivity for these U1
adaptors and activities that certainly must be related to
sequestration of U1 snRNP. A relative increase in
skipping of the endogenous SMN2 exon 7 was also
observed following treatment with both U1A-RAF and
ASO 469508, while the RAF1 ASO, 194166 again had
no effect (Supplementary Figure S4).
U1 adaptor treatment and U1 snRNA knockdown have
similar effects on pre-mRNA processing
We next sought to evaluate and compare transcriptome-
wide effects on expression and splicing following treat-
ment with U1A-RAF1 or direct inactivation of U1
snRNP with ASO 469508. HeLa cells were transfected
with U1A-RAF1, ASO 469508, or ASO 194166, at a con-
centration of 50nM. After 16h, target reduction was con-
ﬁrmed by qRT/PCR (Supplementary Figure S5A) and
affymetrix exon arrays were performed using total
mRNA puriﬁed from the U1 adaptor/ASO-treated cells.
ANOVA was used to detect probes showing signiﬁcant
changes in either direction among the groups. P-values
were then corrected for multiple testing and probes
having adjusted P<0.01 were selected. Compared to un-
treated cells, log2-fold expression changes were found to
be highly signiﬁcant for U1A-RAF1 and U1 ASO 469508
treated, but not for cells treated with RAF1 ASO 194166
(Figure 7a). Comparison of total signatures for each treat-
ment group versus mock-treated (P<1e-3 uncorrected) re-
vealed a highly signiﬁcant overlap (P=2.5e-160) between
genes regulated by U1A-RAF1 and ASO 469508, with
 60% of the U1A-regulated genes in common with the
anti-U1 regulated genes (Figure 7b). ASO 194166 was
found to alter the expression of far fewer genes, which
overlap with those transcripts altered by U1A-RAF1
(P=2.7e-22) or with those regulated by the anti-U1
ASO, 469508 (P=1.2e-20).
It has recently been demonstrated that, distinct from
its role in splicing, U1 snRNP also functions to protect
pre-mRNAs from premature cleavage and polyadenyla-
tion (PCPA) (8). Therefore, regulation of intron and
exon probe intensity was also analyzed in an attempt to
identify changes that may be affecting pre-mRNA pro-
cessing. Treatment with U1A-RAF1 or with anti-U1
ASO 469508 resulted in signiﬁcant increases in intron
probe levels suggesting disruption of pre-mRNA splicing
(Supplementary Figure S5B). Similarly, exon probe ex-
pression changes were signiﬁcant for U1 adaptor and
anti-U1 ASO-treated cells, but not cells treated with the
RNAse H ASO 194166 (Supplementary Figure S5C).
Expression changes for a portion of these transcripts
were conﬁrmed by RT/PCR using nuclear or cytoplasmic
fractions of total RNA treated with U1A-RAF1
(Supplementary Figure S5D). Most transcripts from
U1A-RAF1-treated cells were reduced in the cytoplasmic
RNA fraction. In some cases, the transcripts were also
reduced in the nuclear fraction. However, many of the
transcripts were increased in the nuclear RNA fraction.
This increase of unprocessed mRNA in the nucleus and
corresponding decrease of the spliced transcript in the
cytoplasm is consistent with a model in which U1
adaptors sequester U1 snRNA, effectively lowering the
concentration of U1 snRNP in the cell, leading to PCPA
and/or disruption in mRNA splicing.
DISSCUSSION
U1 adaptors are designed to promote the degradation of
target RNA by tethering the U1 snRNP to the ﬁnal exon
of the mRNA via antisense hybridization (1). Although
U1 adaptors have been reported to inhibit both endogen-
ous and reporter genes in a sequence-speciﬁc manner, a
recent report demonstrating that sequestration of U1
snRNP by RNA decoys can result in the alteration of
Figure 7. Global effects of RAF1 U1 adaptor and anti-U1 ASO treat-
ment. HeLa cells were transfected with U1A-RAF, anti-U1 ASO
469508, or ASO 194166 at 50nM. Total RNA was puriﬁed the follow-
ing day, and mRNA reduction evaluated by qRT/PCR. (a) Affymetrix
exon arrays were performed using total RNA. Data were clustered at
the transcript level using ANOVA-selected genes (N=112, treated
versus control, P<0.1). Shown is log2 regulation for U1 adaptor/
ASO treated cells versus control. (b) Venn diagrams comparing total
signatures for U1 adaptor/ASO versus control. U1A-RAF1, dark
green; ASO 469508, light green; ASO 194166, green.
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mRNAs (7), suggests the possibility that U1 adaptors
may have unintended effects on gene expression. While
it has been postulated that sequestration of U1 snRNP
by low nanomolar amounts of U1 adaptors would have
little effect on the overall splicing given the abundance
of the U1 snRNP in the cell, in light of the high concen-
trations that oligonucleotides are known to achieve in vitro
and in vivo (22), this may not be the case. Further, it
recently been suggested that cellular levels of U1 in
excess of what is required for splicing may be required
to suppress premature cleavage and polyadenylation in
introns (8), so even small changes in levels of U1 may
have deleterious effects on pre-mRNA processing.
Our initial experiments compared the activity of U1
adaptors and ASOs targeting the same sequence. While
the activity of U1 adaptors has been compared with
siRNAs targeting the same sequence, no such comparison
has been made with ASOs designed to utilize an RNAse
H-dependent mechanism. We chose to use RNAse H
ASOs as a speciﬁcity control rather than siRNAs, as the
ASO chemistry is more similar to that of a typical U1
adaptor and we were concerned about making compari-
sons with compounds known to promote degradation
of off-target transcripts (23). While the RNase H ASOs
targeting RAF1 and SMN2 had similar potency for reduc-
tion of the targeted transcript and little signiﬁcant off-
target effect, the target-speciﬁc as well as off-target activity
of the corresponding U1 adaptors was more variable
(Figure 2). The target-speciﬁc activity observed for U1A-
RAF1 was in close agreement the previously published
activity for this compound (1). However, we observed sig-
niﬁcantly more off-target reduction which, in the case of
PTEN mRNA, was nearly equivalent to reduction of the
intended target (Figure 2c). This may simply be a conse-
quence of the difference in non-targeted transcripts
which we chose to evaluate. The potency of off-target
activity may also be related to speciﬁc sequence of each
U1 adaptor. For instance, U1A-SMN2 was clearly more
potent than U1A-RAF1; however, the potency of off-
target mRNA reduction, though signiﬁcant, was less,
relative to target-speciﬁc reduction, than that of U1A-
RAF (Figure 2a and b). Interestingly, U1A-PCSK9 had
potency similar to that of U1A-SMN2; however, there was
almost no difference between target-speciﬁc and off-target
activity for this compound (Figure 3c). While there
does appear to be a window of speciﬁcity for some U1
adaptors, none of the U1 adaptors that we evaluated
were free of off-target activity. Even for the most speciﬁc,
the ratio of on- to off-target activity was  7-fold. In
contrast, off-target IC50’s were never reached for RNAse
H-dependent ASOs, despite similarities in target-speciﬁc
potency.
Treatment of cells with the RNAse H-dependent U1
snRNA ASO, 469508, resulted in cleavage of the
50-leader sequence responsible for 50-splice site recognition
by the U1 snRNP (Figure 3b) (24). For some transcripts,
such as PCSK9 and YY1, reduction of U1 snRNA using
this ASO resulted in activity nearly indistinguishable from
the off-target activity promoted by the U1 adaptor
(Figures 3c, 4a and b), while for other transcripts, such
as SMN2 and RAF1, the off-target effect of the U1
adaptor was greater than that observed by directly target-
ing U1 snRNA. These data suggest that at least a portion
of the observed U1 adaptor off-target activity may be
related to U1 snRNP sequestration; however, certain tran-
scripts appear to be more susceptible to the effects of U1
reduction than others. It has recently been shown that
when levels of U1 were reduced, pre-mRNAs containing
intronic polyadenylation signals are prematurely cleaved
and polyadenylated (PCPA) within the intron (8). Our
RNAse H protection assays clearly showed that U1
adaptors effectively reduced the levels of functional U1
snRNP at concentrations consistent with those at which
off-target transcript reduction was observed (compare
Figures 3c and 5b). Therefore, it is likely that differences
in the presence of intronic poly(A) signals or in the ability
of a particular U1 adaptor to sequester U1 snRNA, may
account for differences in off-target activity between tran-
scripts. There did appear to be some correlation
of off-target activity with the afﬁnity of U1 adaptors for
U1 snRNA, as U1A-SMN2 and U1A-PCSK9 blocked U1
snRNA more effectively than did U1A-RAF1 (Figure 5).
It has been suggested that vulnerability to PCPA would be
expected to increase with increasing intron size if U1
snRNP is not available to suppress utilization of cryptic
polyadenylation signals. Indeed, SMN2 which was rela-
tively resistant to the non-speciﬁc effects of U1 adaptor
treatment and U1 snRNA reduction, has fewer, and on
average, shorter introns, than either RAF1 or PTEN.
To further explore the mechanism of U1 adaptor-
mediated off-target mRNA reduction, we compared the
effect of U1 adaptor and ASO treatment on splicing and
expression using a tetracycline inducible SMN2 minigene
construct (Figure 6) (25). In agreement with Roca and
Krainer (7), who used U1-speciﬁc RNA decoys to seques-
ter U1 snRNP, we found that ASO 469508-mediated
cleavage of the 50-end of U1 snRNA resulted in reduced
SMN2 exon 7 inclusion in the TET-inducible mini gene
(Figure 6d). In addition, a signiﬁcant increase in the level
of the unspliced pre-mRNA for the mini gene was ob-
served. It is likely that U1 reduction differentially affects
splicing by favoring interactions of exons with the more
favorable splice site consensus sequences (26,27) when
U1snRNP is present in limiting quantities. Note that re-
duction of U4 snRNA resulted in an equal reduction
of the skipped and full-length messages with a correspond-
ing increase in the level of the pre-mRNA (see also
Supplementary Figure S3). U2 and U6 snRNA were
also reduced in this system with no effect on the ratios
of the skipped to full-length mRNA (data not shown).
Treatment with U1 adaptors resulted in an expression
proﬁle similar to that observed with U1 reduction; i.e.
an increase in pre-mRNA levels and the ratio of skipped
to full-length spliced mRNA. Together these data suggest
that U1 adaptors may have unintended effects on mRNA
splicing as the result of sequestration of U1 snRNP. Our
results differ from those previously reported by
Goraczniak et al. (1) who observed no effects of treatment
with U1 adaptors on splicing of a reporter gene or of four
endogenous genes. We chose to evaluate effects on splicing
near the IC80 for the U1 adaptor rather than the IC50.A sa
e71 Nucleic Acids Research, 2011,Vol. 39,No. 10 PAGE 10 OF 12result, we treated cells with  10-fold more U1 adaptor. It
is also possible that our tetracycline-inducible splicing
reporter system is more sensitive to the effects of U1 re-
duction. However, inclusion of exon 7 in the endogenous
SMN2 gene was also reduced by U1A-RAF1 or anti-U1
ASO treatment (Supplementary Figure S4). Our data
suggest that U1 adaptors vary in their ability to promote
off-target mRNA splicing and reduction (Figures 3c and
6d), but that, at least in some cases, they are no more
speciﬁc than is reducing U1 snRNA.
In a previous study, cells treated with U1 adaptors tar-
geting PCSK9 were assessed by microarray proﬁling, and
compared head-to-head with an siRNA directed against
PCSK9 (1). The two methods of transcript reduction were
determined share a high degree of overlap, with 93% con-
cordance in gene expression changes and it was concluded
that U1 adaptors do not have a signiﬁcant off-target
proﬁle as compared with siRNA. However, it is possible
that the high degree of concordance resulted from com-
parison of two treatments both of which may produce
signiﬁcant off-target effects (28). In fact, signiﬁcant
changes in gene expressions were observed in both U1
adaptor and siRNA-treated groups (1). We used
Affymetrix Exon Arrays to evaluate off-target effects of
treatment with U1A-RAF1 and anti-U1 ASO 469508
since they had similar potency for mRNA reduction
(Figures 3 and 4). Given that signiﬁcant and widespread
off-target activity due to seed region homology has been
reported for siRNAs (23,28), while the hybridization of a
typical 18–20nt ASO has been determined to approach
nearly theoretical speciﬁcity (29,30), we chose employ
the corresponding RNAse H-dependent ASO as our ex-
perimental control. While treatment with the correspond-
ing ASO produced few signiﬁcant changes in gene
expression relative to mock-treated control cells, treat-
ment with both U1A-RAF1 and ASO 469508 lead to sig-
niﬁcant changes in gene regulation (Figure 7a).
Importantly, a large degree of overlap was observed be-
tween the U1A-RAF1 and the anti-U1 ASO 469508
groups, while the RAF1 ASO regulated far fewer genes
which overlapped signiﬁcantly with those regulated by
U1A-RAF1 or ASO 469508 (Figure 7b). Further
analysis of the array data revealed that speciﬁc intron and
exon probes were increased or decreased in U1A-RAF
and anti-U1 ASO 469508 treated cells relative to control
(Supplementary Figure S5B and C). Several of these tran-
scripts were conﬁrmed by qRT/PCR. Consistent with dis-
ruption of splicing and PCPA, the pre-mRNA for a
signiﬁcant proportion of the transcripts was increased in
the nucleus of cells treated with U1A-RAF1 or ASO
469508 with a corresponding decrease in the spliced
mRNA in the cytoplasm (Supplementary Figure S5D).
Our data conﬁrm that U1 adaptors are capable of
reducing targeted mRNA transcripts at concentrations
comparable to that obtained with chimeric ASOs support-
ing RNAse H-mediated cleavage of the target. However,
quantitative RT/PCR with multiple U1 adaptors, PCR
arrays and Affymetrix exon arrays all show considerable
reduction of non-target transcripts by U1 adaptors as
compared to ASOs at concentrations where phenotypic
effects would be expected to occur. It is possible that a
portion of the observed non-speciﬁc activity may be the
consequence off-target hybridization and subsequent
deadenylation/degradation of the transcript (31), or the
result of RNAse H-mediated cleavage of non-target se-
quences bound by the LNA/DNA portion the oligo-
nucleotide. All U1 adaptors used in this study had
several DNA gaps of three or four bases. It has been
shown that DNA gaps of four bases can efﬁciently
direct RNAse H cleavage of a target (32); however, no
target or off-target reduction of mRNA was observed
when cells were treated with only the target portion of
the U1A-RAF1 adaptor (Figures 1 and 5b). Our data
suggest that a signiﬁcant portion of U1 adaptor-mediated
off-target mRNA reduction is the result of sequestering of
U1 snRNP. For some U1 adaptors such as U1A-SMN2 a
narrow window between on- and off-target potency was
observed, while for others such as U1A-RAF1 and U1A-
PCSK9 there was very little difference. Clearly, U1
adaptor sequences will require careful screening to minim-
ize U1 snRNP sequestration and establish maximal
speciﬁcity.
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